NCT00406016 - Acute Safety, Tolerability, Feasibility and Pharmacokinetics of Intrath. Administered ATI355 in Patients With Acute SCI | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions

Acute Spinal Cord Injury

Interventions

DRUG

ATI355

Trial Locations (14)

Novartis Investigative site, Zurich

Novartis Investigative site, Hamburg

Novartis Investigative site, Bad Wildungen

Novartis Investigative site, Bochum

Novartis Investigative site, Heidelberg

Novartis Investigative site, Tübingen

Novartis Investigative site, Karlsbad-Lagensteinbach

Novartis Investigative site, Murnau am Staffelsee

Novartis Investigative site, Ulm

Novartis Investigative site, Calgary

Novartis Investigative site, Montreal

Novartis Investigative site, Toronto

Novartis Investigative site, Vancouver

Novartis Investigative site, Bayreuth